VKTX Projected Dividend Yield
Viking Therapeutics Inc ( NASDAQ : VKTX )Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is focused on the development of therapies for treatment of metabolic and endocrine disorders. Co.'s clinical programs include VK2809, an orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders, which is being evaluated in a Phase II b study for the treatment of biopsy-confirmed non-alcoholic steatohepatitis (NASH) and fibrosis. 20 YEAR PERFORMANCE RESULTS |
VKTX Dividend History Detail VKTX Dividend News VKTX Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |